Introduction: Donor lymphocyte infusion (DLI) is one of the effective options for post-
transplant disease control of myelodysplastic syndrome (MDS). Its success or failure …

Allogeneic hematopoietic stem cell transplantation (HSCT) improves outcomes for
myelodysplastic syndrome (MDS) patients, but relapse rates remain high, and post-relapse …

Donor lymphocyte infusion has become established as a salvage therapy for patients with
hematological disorders relapsing after allogeneic bone marrow transplantation (BMT). The …

Simple Summary Allogeneic stem cell transplantation (allo-SCT) represents the only
potentially curative treatment for high-risk acute myeloid leukemia (AML) and …

Allogeneic hematopoietic cell transplantation (HCT) represents a potentially curative
approach for patients with myelodysplastic syndromes (MDSs). While a large proportion of …

Introduction: Donor lymphocyte infusion (DLI) is used to induce remission in patients who
relapse after allogeneic stem cell transplantation (allo-HSCT). During the last decade, the …

The efficacy of donor lymphocyte infusion (DLI) without chemotherapy was investigated and
compared with that of chemotherapy prior to DLI (Chemo-DLI) in patients who were minimal …

Relapse occurs in 30%-50% of recipients of T cell–depleted (TCD) reduced-intensity
conditioned (RIC) hematopoietic stem cell transplantation (HSCT) for acute myelogenous …

Objectives Allogeneic hematopoietic stem cell transplantation (HSCT) effectively treats high‐
risk myeloid neoplasms, but relapses post‐HSCT, particularly in acute myeloid leukemia …

Introduction This longitudinal study was based on the outcomes of Donor Lymphocyte
Infusion (DLI) for falling peripheral blood (PB) CD34+ and CD3+ donor chimerism (DC) …